1. MLTX stock plummeted over 90% on Monday after Phase 3 trial results. 2. Sonelokimab achieved significant HiSCR75 responses at week 16 in trials. 3. Higher placebo response in VELA-2 trials may impact perceived drug efficacy. 4. Statistically significant results across all key endpoints were reported. 5. Favorable safety profile noted with no new safety signals.
The over 90% drop indicates severe market reaction to trial results, reflecting low investor confidence. Similar past outcomes, such as failures in Phase 3 trials, have resulted in substantial stock declines.
The article directly discusses MLTX's trials and immediate stock price impact due to results.
Immediate investor sentiment is significantly negative; recovery can be unlikely in the near term. Historical instances, like those seen with other biotech stocks, demonstrate that trial failures lead to swift stock downturns.